Vertex Pharmaceuticals Inc. (VRTX) Director Joshua S. Boger Sells 6,500 Shares
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the company’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $90.98, for a total transaction of $591,370.00. Following the completion of the transaction, the director now owns 274,725 shares in the company, valued at $24,994,480.50. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 94.42 on Tuesday. The firm’s market cap is $23.42 billion. Vertex Pharmaceuticals Inc. has a 12 month low of $73.31 and a 12 month high of $134.71. The stock has a 50 day moving average of $83.48 and a 200 day moving average of $89.56.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by $0.02. Vertex Pharmaceuticals had a negative net margin of 13.45% and a negative return on equity of 5.31%. The company earned $413.78 million during the quarter, compared to analyst estimates of $423.53 million. During the same quarter in the previous year, the company posted ($0.13) EPS. The company’s quarterly revenue was up 33.6% on a year-over-year basis. On average, equities research analysts expect that Vertex Pharmaceuticals Inc. will post $0.78 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in Vertex Pharmaceuticals by 46.9% in the second quarter. FMR LLC now owns 22,227,104 shares of the pharmaceutical company’s stock valued at $1,911,975,000 after buying an additional 7,092,351 shares during the period. Jennison Associates LLC increased its stake in Vertex Pharmaceuticals by 74.2% in the third quarter. Jennison Associates LLC now owns 5,180,761 shares of the pharmaceutical company’s stock valued at $451,814,000 after buying an additional 2,205,961 shares during the period. TimesSquare Capital Management LLC acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at approximately $61,066,000. Capital World Investors increased its stake in Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock valued at $1,944,119,000 after buying an additional 599,586 shares during the period. Finally, Eaton Vance Management increased its stake in Vertex Pharmaceuticals by 142.8% in the second quarter. Eaton Vance Management now owns 994,957 shares of the pharmaceutical company’s stock valued at $85,586,000 after buying an additional 585,172 shares during the period. Institutional investors and hedge funds own 96.20% of the company’s stock.
A number of equities analysts have recently issued reports on VRTX shares. Jefferies Group reiterated a “buy” rating and set a $107.00 price objective (up from $102.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, July 31st. Morgan Stanley dropped their price objective on shares of Vertex Pharmaceuticals from $140.00 to $139.00 and set an “overweight” rating on the stock in a research note on Thursday, July 28th. JMP Securities reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. Leerink Swann set a $112.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, September 17th. Finally, RBC Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 12th. Fourteen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $108.63.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.